Nikolaos Sfikas

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

Howard Feldman, Steven H. Ferris, Bengt Winblad et al. · The Lancet Neurology · 2007 · 337 citations

Medicine, Neurology, Pharmacology +14

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

Richard M. Nixon, Niklas Bergvall, Davorka Tomic et al. · Advances in Therapy · 2014 · 91 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +15

Synergistic effect of apolipoprotein E ε4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease

Roger Lane, Howard Feldman, Joanne M. Meyer et al. · Pharmacogenetics and Genomics · 2008 · 61 citations

Life Sciences, Genetics, Neurology +17

The NK₁‐receptor antagonist TKA731 in painful diabetic neuropathy: A randomised, controlled trial

Søren H. Sindrup, Ana Graf, Nikolaos Sfikas · European Journal of Pain · 2005 · 58 citations

Medicine, Pharmacology, Pharmacotherapy +17

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis

Frederik Barkhof, Remko de Jong, Nikolaos Sfikas et al. · Multiple Sclerosis Journal · 2014 · 45 citations

Life Sciences, Neurology, Pharmacotherapy +16